UBS analyst Kevin Caliendo raised the firm’s price target on Evolent Health (EVH) to $15 from $14 and keeps a Buy rating on the shares. Evolent Health has better visibility into its future financials and growth algorithm than it did just five months ago following the repricing and recontracting of its major customer contracts, the analyst tells investors in a research note. The first quarter was a first step toward regaining credibility with shareholders and UBS sees the risk-reward as positive.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EVH:
- Evolent Health Reports Strong Q1 2025 Growth
- Evolent Health: Strong Financial Performance and Growth Potential Justify Buy Rating
- Evolent Health reports Q1 adjusted EPS 6c, consensus 10c
- Evolent Health sees Q2 revenue $440M-$470M, consensus $503.67M
- Evolent Health sees 2025 revenue $2.06B-$2.11B, consensus $2.07B
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue